Revolutionizing Healthcare with Early Disease Detection
Quanterix, a company developing technology designed to enable earlier disease detection, made its market debut on Thursday. Shares of the company surged after pricing at $15 a share, and opening at $16.25 a share. Kevin Hrusovsky, CEO of Quanterix, was with us to discuss how the company plans to revolutionize healthcare.
The fourth-leading cause of death is drug side effects, and drugs only work half the time, says Hrusovsky. He believes that if you can personalize the drugs, you have an opportunity to improve the whole pharmaceutical industry.
Quanterix is developing technology that will digitize how they see into blood, and help to see disease long before there are symptoms. Rocket science is being deployed into the blood, says Hrusovsky. He says that if you can see biomarkers and incorporate into fitbits, it can really help improve health.
A Montana judge on Monday sided with young environmental activists who said state agencies were violating their constitutional right to a clean and healthful environment by permitting fossil fuel development without considering its effect on the climate.
Alzheimer’s mainly affects the elderly, who are eligible for Medicare, but people under 65 — even, rarely, as young as their 30s — also can get diagnosed. They are more likely to have commercial coverage.
Some doctors say the drug should be held for three weeks before sedation to accommodate the delayed emptying of the stomach, which can cause patients to inhale food and liquid into their lungs.
